drug:orforglipron
A high quality GLP1 pill: once-daily Orforglipron
We take a look at the most recent set of results from Orforglipron, the oral GLP1 from Eli Lilly
Hims will sell generic Semaglutide in 2026
Hims is going to start selling generic Semaglutide in 2026, long before US patents expire. How?
Novo Nordisk is introducing a higher dose of Wegovy
Novo Nordisk is looking to introduce a new higher dosage of Semaglutide (Wegovy) -- we take a look at the studies they *didn't* submit.
Novo's expanding collaboration with Weight Watchers
Novo Nordisk expanded their collaboration with Weight Watchers, offering an introductory price of $299
Less for Less: CVS drops Zepbound for Wegovy
CVS Health drops coverage of the more effective Tirzepatide (Zepbound) for Semaglutide (Ozempic, Wegovy) and Liraglutide (Saxenda).
If GLP1 is so great, why don't people stick with it?
Why are so few people able to stay on GLP1s for 3 years? We dig into the analysis & report by Prime Therapeutics.
A glowing endorsement of GLP1s by cardiologists
Reflection on the ACC's endorsement of GLP1s as a first-line approach to weight management and improving cardiovascular outcomes.
A new risk? Macular Degeneration
We explore the new GLP1 risk factor for macular degeneration (nAMD) that has been reported in a study published to JAMA.
Updates from MariTide & Orforglipron research
MariTide and Orfoglipron updates from the ADA 85th Science Sessions conference in June, with the key results that were announced.
After two months, Novo Nordisk and HIMS part ways
Novo Nordisk and HIMS end their partnership that brought cheaper Wegovy (Semaglutide) to customers of HIMS.
Preserving muscle: GLP1s with Bimagrumab
We deep dive on Bimagrumab, a muscle-preserving booster to GLP1 receptor agonists like Ozempic, Wegovy, Mounjaro, Zepbound and others.
Novo Nordisk patent protections lapse in Canada
Novo Nordisk's patent protections lapse early after forgetting to pay a small fee allows a Canadian Generic to get to market faster.
A challenge to Eli Lilly's Tirzepatide patent
Empower Pharmacy has challenged the patent on Eli Lilly's Tirzepatide, creating possibly the biggest possible shock to come to compounding GLP1s.